Avista Capital Partners today announced it has entered into a definitive agreement to acquire Probo Medical for an undisclosed amount.
Varsity Healthcare Partners’ Probo Medical is a Tampa-based medical imaging company that sells and repairs ultrasound probes. It has 14 facilities in the U.S. in Europe and has a global supply chain.
Get the full story on our sister site, Medical Design & Outsourcing.
Boston Scientific (NYSE:BSX) announced today that it closed its acquisition of Baylis Medical for $1.75 billion upfront.
On Oct. 6, 2021, Boston Scientific announced it had agreed to acquire the Canada-based company in an effort to expand its electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms, as well as a family of guidewires, sheaths and dilators used to support left heart access.
The Baylis platforms offer advanced transseptal puncture. Boston Scientific said when it announced the agreement to acquire Baylis that the company’s platforms are clinically proven to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart in procedures such as AFib ablation, left atrial appendage closure (LAAC) and mitral valve interventions.
Marlborough, Massachusetts-based Boston Scientific expects the $1.75 billion ac…
Henry Schein (NSDQ:HSIC) shares ticked up this morning on fourth-quarter results that topped the consensus forecast.
The Melville, New York-based company posted profits of $147.2 million, or $1.05 per share, on sales of $3.3 billion for the three months ended Dec. 25, 2021, for a 3.2% bottom-line gain on sales growth of 5.2%.
Adjusted to exclude one-time items, earnings per share were $1.07, 16¢ ahead of Wall Street, where analysts were looking for sales of $3.1 billion.
Henry Schein’s dental sales increased by 9.4% year-over-year, although the company’s $1.1 billion in medical sales represented a 3.2% dip from 2021. Excluding sales of personal protective equipment (PPE) and COVID-19-related products, sales increased by 3.6%, as PPE and COVID-19-related products were in higher demand this time last year, according to a news release.
“Despite the impact of the global COVID-19 pandemic, we are pleased to report excellent full-year 2021 f…
The Philips Capsule Medical Device Information Platform (MDIP) can now integrate with more than 1,000 unique types of medical devices, the Dutch medtech giant said in October.
To help understand what’s possible in medtech with the cloud, Medical Design & Outsourcing asked two leaders at Philips — Virtual Care Solutions Business Category Leader Christine Storm and Informatics Transformational Programs Leader Bas Kuppens — to offer their perspectives.
Get the full story at our sister site, Medical Design & Outsourcing.
3M (NYSE:MMM) today told investors that it is projecting single-digit growth for the 2022 fiscal year as respirator mask demand slows.
The St. Paul, Minnesota-based manufacturing and material science giant said in its Virtual Strategic Update that it expects organic sales growth to be in the range of 2% to 5% for this fiscal year. It estimates earnings to be in the range of $10.15 to $10.65 per share. 3M’s healthcare segment expects organic sales growth to be in the “mid-single digits” for the year.
With more relaxed COVID-19 guidelines across the country, 3M forecasts that the reduced demand of disposable face masks will affect its earnings per share by an estimated –45¢, or a 2% loss in organic sales growth. 3M assumes Q1 2022 will have a lower pandemic-related disposable respiratory demand of $100 million to $150 million year-on-year.
The company has been on the frontlines of combatting the COVID-19 pandemic by providing essential pe…
Campbell, California-based Imperative Care designed the Zoom POD to enable faster time to clot capture during critical mechanical thrombectomy procedures for ischemic stroke patients. The company touts Zoom POD as the first and only sterile field clot filter device.
Get the full story at our sister site, Medical Tubing & Extrusion.
Boston-based Datar designed its TriNetra-Prostate blood test to detect early-stage prostate cancer. It follows the company’s early-stage breast cancer detection test, which garnered a breakthrough nod in November 2021.
The company said in a news release that studies show that TriNetra-Prostate can detect early-stage cancer with high accuracy (>99%) without any false positives. The test requires 5 mL of blood and has the indication for males of age 55-69 years with serum PSA of 3 ng/mL or higher.
Datar Cancer Genetics based its test upon the detection of prostate adenocarcinoma-specific Circulating Tumor Cells (CTCs) in the blood. The test already holds CE mark and is already available in Europe as “Trublood-Prostate.”
“The breakthrough device designation is a rec…
Myomo (NYSE:MYO) announced today that new research demonstrated benefits with its MyoPro myolectric orthosis.
Results from the study, funded by the U.S. Army Medical Research Acquisition Activity, and supported by the Office of Secretary of Defense for Health Affairs, were published in the peer-reviewed journal Frontiers in Neurology. Data showed “statistically significant improvements” in a number of motor function measurements.
The study observed 13 individuals with chronic moderate-to-severe arm weakness from stroke or traumatic brain injury, with outcomes collected through in-therapy sessions and at-home use, according to a news release. Dr. Svetlana Pundik, the lead investigator and grant recipient, along with colleagues at the Louis Stokes Cleveland Veterans Administration Medical Center, conducted the study.
Authors stated that gains were seen at week three, increased further during the in-clinic phase and were maintained during the at…
Elon Musk’s brain implant startup, Neuralink, and the University of California, Davis, have been accused of “egregious violations of the Animal Welfare Act” by the Physicians Committee for Responsible Medicine (PCRM), citing documents obtained through a public records lawsuit.
The nonprofit — which successfully pressured U.S. medical schools including Johns Hopkins to stop using live pigs for surgical training — is asking the USDA to investigate the research facilities at UC Davis and Neuralink, saying the “carelessness by these facilities resulted in the suffering and death of several monkeys.”
Neuralink did not respond to a request for information from Medical Design & Outsourcing, but UC Davis said Neuralink researchers used facilities at the school’s California National Primate Research Center, with university staff providing veterinary care and monitoring of the monkeys. The university said the research protocols were approved by the UC Davis Instituti…
CroíValve this week announced that it raised €8 million ($9 million) in a Series A fundraising round to support a feasibility clinical study of its tricuspid valve system.
The Dublin-baed company designed its Duo coaptation valve system to treat tricuspid regurgitation (TR), which is a severe heart condition that occurs when the tricuspid valve fails to close properly. The condition results in blood being pumped back into the right atrium and venous system.
CroíValve designed the Duo system with a computation valve implant that works with the native tricuspid valve to restore function. It is delivered percutaneously and is secured using an anchor system that avoids the right heart chamber and native valve apparatus.
Duo is implanted using standard imaging for a broad range of patients. CroíValve said the device’s approach has already “generated convincing pre-clinical and clinical data” and that temporary clinical implants have shown to…
Johnson & Johnson’s (NYSE:JNJ) DePuy Synthes announced that it acquired CrossRoads Extremity Systems.
Tennessee-based CrossRoads Extremity Systems develops a range of procedure-specific, sterile-packed implants and instrumentation systems cleared for lower extremity indications. The company grew into a leader in the foot and ankle space with backing from HealthpointCapital.
According to a news release, in acquiring CrossRoads, DePuy Synthes adds a number of differentiated products to its portfolio, including the miniBunion 3D, dynaBunion 4D and DynaFoce staple compression plates.
CrossRoads designed miniBunion as a minimally invasive solution for metatarsal bone osteotomy, while it developed the dynaBunion lapidus system as an option for lapidus bunionectomy and a provider of instrumentation and implants to correct bunions in four dimensions through smaller incisions.
DynaForce staple compression plates combine stability with dynamic continuou…